Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07867171
PHASE1

A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on Velzatinib

Sponsor: GlaxoSmithKline

View on ClinicalTrials.gov

Summary

This study evaluates the effect of moderate and severe renal impairment on the pharmacokinetics (PK) of velzatinib compared with normal renal function.

Official title: A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of Velzatinib in Participants With Moderate or Severe Renal Impairment Compared to Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-10-23

Completion Date

2027-09-09

Last Updated

2026-10-09

Healthy Volunteers

Yes

Interventions

DRUG

Velzatinib

Velzatinib will be administered.